NEVVI Medicare utilization intelligence

← back

NABBOUT, NASSIMM.D. NPI 1528029147 Clinician

Hematology-Oncology · WICHITA, KS

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 31 years since medical school (class of 1995, self-reported to CMS)
Location WICHITA, KS · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 99 codes billed · 375,191 disclosed services (CY2024 — most recent year in data)
Current groups
member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Group affiliation since 2019

20192026
SHEA PHYSICAL THERAPY SPECIALISTS LLC
2026
CANCER CENTER OF KANSAS PA
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2026-04

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J1439 Injection, ferric carboxymaltose, 1 mg
J9299 Injection, nivolumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1627 Injection, granisetron, extended-release, 0.1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J0897 Injection, denosumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J9173 Injection, durvalumab, 10 mg
J9171 Injection, docetaxel, 1 mg
J9022 Injection, atezolizumab, 10 mg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
J1930 Injection, lanreotide, 1 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J9304 Injection, pemetrexed (pemfexy), 10 mg
J9228 Injection, ipilimumab, 1 mg
J9301 Injection, obinutuzumab, 10 mg
J9312 Injection, rituximab, 10 mg
J2796 Injection, romiplostim, 10 micrograms
J9355 Injection, trastuzumab, excludes biosimilar, 10 mg
J9041 Injection, bortezomib, 0.1 mg
36415 Insertion of needle into vein for collection of blood sample
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
85007 Microscopic examination for white blood cells with manual cell count
J2919 Injection, methylprednisolone sodium succinate, 5 mg
80053 Blood test, comprehensive group of blood chemicals
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96413 Administration of chemotherapy into vein, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
J9190 Injection, fluorouracil, 500 mg
J0640 Injection, leucovorin calcium, per 50 mg
J9045 Injection, carboplatin, 50 mg
J9181 Injection, etoposide, 10 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96415 Administration of chemotherapy into vein, each additional hour
J2469 Injection, palonosetron hcl, 25 mcg
96375 Injection of additional new drug or substance into vein
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J1200 Injection, diphenhydramine hcl, up to 50 mg
J9060 Injection, cisplatin, powder or solution, 10 mg
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
J3475 Injection, magnesium sulfate, per 500 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96361 Infusion into a vein for hydration, each additional hour
J9000 Injection, doxorubicin hydrochloride, 10 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
82378 Carcinoembryonic antigen (cea) protein level
J3490 Unclassified drugs
84443 Blood test, thyroid stimulating hormone (tsh)
84439 Thyroxine (thyroid chemical), free
J7030 Infusion, normal saline solution , 1000 cc
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
83615 Lactate dehydrogenase (enzyme) level
99441 Telephone medical discussion with physician, 5-10 minutes
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96523 Irrigation of implanted venous access drug delivery device
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
96411 Administration of additional new drug or substance into vein using push technique
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
83735 Magnesium level
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96360 Infusion into a vein for hydration, 31-60 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
84550 Uric acid level, blood
71260 Ct scan of chest with contrast
82607 Cyanocobalamin (vitamin b-12) level
85046 Red blood count automated, with additional calculations
85651 Red blood cell sedimentation rate, to detect inflammation, non-automated
99195 Drawing of blood for a medical problem
84153 Psa (prostate specific antigen) measurement, total
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
Q9965 Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml
74177 Ct scan of abdomen and pelvis with contrast
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
81000 Manual urinalysis test with examination using microscope, non-automated
86301 Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
71250 Ct scan of chest without contrast
74176 Ct scan of abdomen and pelvis without contrast
74178 Ct scan of abdomen and pelvis before and after contrast
99442 Telephone medical discussion with physician, 11-20 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.